What question did this study set out to answer?

To evaluate the safety, clinical efficacy, and disease clearance of frontline combination therapy with vemurafenib and obinutuzumab in patients with previously untreated hairy cell leukemia.

September 21, 2023NEJM EvidenceOpen Access

Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

View Full Paper

Ask AI

Bookmark

Authors

JPJae H. ParkMemorial Sloan Kettering Cancer Center SDSean M. DevlinMemorial Sloan Kettering Cancer Center BDBenjamin H. DurhamRutgers, The State University of New Jersey

Discussion

Member takes

Implication

Single-arm clinical trial demonstrates a 90% complete remission rate with vemurafenib plus obinutuzumab in untreated hairy cell leukemia, suggesting a potent chemotherapy-free frontline regimen.

Key Points

To evaluate the safety, clinical efficacy, and disease clearance of frontline combination therapy with vemurafenib and obinutuzumab in patients with previously untreated hairy cell leukemia.
Conducted a single-arm, multicenter interventional clinical study (NCT03410875) enrolling 30 patients with previously untreated hairy cell leukemia.
Administered oral vemurafenib (960 mg twice daily) for four cycles with obinutuzumab added during cycles 2 to 4, monitoring complete remission, safety, minimal residual disease (MRD), and BRAF allele burden.
Complete remission was achieved in 27 of 30 patients (90%; 95% CI, 73 to 98), while 3 patients discontinued early due to adverse events.
Among the 27 patients achieving complete remission, 26 reached MRD negativity (96%; 95% CI, 81 to 99), and BRAFV600E was undetectable via ddPCR in all 21 evaluable patients.
At a median follow-up of 34.9 months (95% CI, 29.6 to 36.9), no patients experienced disease relapse, with rash and arthralgia representing the most frequent treatment-related adverse events.

Cite This Study

Park et al. (2023) studied this question.

synapsesocial.com/papers/6a7126e2ac440176ef29d58d https://doi.org/10.1056/evidoa2300074

View Full Paper

Ask AI

Bookmark

Implication

Single-arm clinical trial demonstrates a 90% complete remission rate with vemurafenib plus obinutuzumab in untreated hairy cell leukemia, suggesting a potent chemotherapy-free frontline regimen.

Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider